Healthcare services provider Optum co-led a $21.5m series A round for Singapore-based medical information software developer Holmusk yesterday through strategic investment vehicle Optum Ventures.
The round was co-led by private equity firm Health Catalyst Capital and also featured Heritas Capital, which was formed by holding company IMC Group, in addition to unnamed private investors.
Holmusk is building a software platform that is collecting large amounts of information on real-life cases in order to provide evidence for physicians using behavioural health treatments for mental health conditions and chronic diseases.
Vijay Barathan, a senior principal at Optum Ventures, is joining the company’s board of directors alongside Charles Boorady, founder and managing director of Health Catalyst Capital.
Barathan said: “Our team is encouraged by Holmusk’s evidence-based approach to improving care for people suffering from behavioural health disorders, and we look forward to working closely with the Holmusk team to support the next phase of growth.”
The company had previously completed a $9.75m pre-series A round in September 2018, securing the funding from Heritas Capital and undisclosed new and existing investors.
Hoolmusk founder and CEO Nawal Roy said: “In situations like today, the need for real-world evidence is more pronounced than ever. We are fortunate to bring on partners like Optum Ventures and Health Catalyst Capital who understand the importance and are excited to join us in our mission to drive evidence-based care.”
